Henry Lewi
Overview
Explore the profile of Henry Lewi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reddy D, Peters M, Shah T, van Son M, Bertoncelli Tanaka M, Huber P, et al.
Eur Urol
. 2022 Feb;
81(4):407-413.
PMID: 35123819
Background: Focal therapy aims to treat areas of cancer to confer oncological control whilst reducing treatment-related functional detriment. Objective: To report oncological outcomes and adverse events following focal high-intensity focused...
2.
van Son M, Peters M, Reddy D, Shah T, Hosking-Jervis F, Robinson S, et al.
Prostate Cancer Prostatic Dis
. 2021 May;
24(4):1120-1128.
PMID: 33934114
Background: For localised prostate cancer, focal therapy offers an organ-sparing alternative to radical treatments (radiotherapy or prostatectomy). Currently, there is no randomised comparative effectiveness data evaluating cancer control of both...
3.
Shah T, Reddy D, Peters M, Ball D, Kim N, Gomez Gomez E, et al.
Prostate Cancer Prostatic Dis
. 2021 Jan;
24(2):567-574.
PMID: 33504940
Introduction: Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). Methods: Using prospective multicentre databases...
4.
Huber P, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al.
World J Urol
. 2020 Jul;
39(4):1115-1119.
PMID: 32638084
Objective: To compare cancer control in anterior compared to posterior prostate cancer lesions treated with a focal HIFU therapy approach. Materials And Methods: In a prospectively maintained national database, 598...
5.
Huber P, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al.
J Endourol
. 2020 Apr;
34(6):641-646.
PMID: 32253928
Analysis of treatment success regarding oncological recurrence rate between standard and dose escalation focal high-intensity focused ultrasound (HIFU) of prostate cancer. In this analysis of our prospectively maintained HIFU (Sonablate...
6.
Lovegrove C, Peters M, Guillaumier S, Arya M, Afzal N, Dudderidge T, et al.
BJU Int
. 2020 Jan;
125(6):853-860.
PMID: 31971335
Objectives: To assess change in functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) treatment compared with outcomes after one focal HIFU treatment. Patients And Methods: In this multicentre...
7.
Huber P, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al.
J Urol
. 2020 Jan;
203(4):734-742.
PMID: 31928408
Purpose: We determined whether prostate specific antigen criteria after focal high intensity focused ultrasound to treat prostate cancer could diagnose treatment failure. Materials And Methods: A total of 598 patients...
8.
Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, et al.
Eur Urol
. 2018 Jul;
74(4):422-429.
PMID: 29960750
Background: Clinically significant nonmetastatic prostate cancer (PCa) is currently treated using whole-gland therapy. This approach is effective but can have urinary, sexual, and rectal side effects. Objective: To report on...
9.
Dickinson L, Arya M, Afzal N, Cathcart P, Charman S, Cornaby A, et al.
Eur Urol
. 2016 Mar;
70(4):668-674.
PMID: 26951947
Background: High-intensity focused ultrasound (HIFU) is a minimally-invasive treatment for nonmetastatic prostate cancer. Objective: To report medium-term outcomes in men receiving primary whole-gland HIFU from a national multi-centre registry cohort....
10.